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The Emerging Role of Lipoprotein-associated Phospholipase A2 in Cerebrovascular
Disease
S.K. Kakkos*, I.A. Tsolakis
Department of Vascular Surgery, University of Patras Medical School, Patras 26 504, GreecePrevious studies have demonstrated increased serum levels of
lipoprotein-associated phospholipase A2 (Lp-PLA2) in cardiovascular
and cerebrovascular disease, including incident stroke,1 and recur-
rent TIA or stroke.2,3 Lp-PLA2 is an enzyme derived from inﬂamma-
tory leukocytes involved in the metabolism of oxidized LDL by
generating mediators (lysophosphatidylcholine and oxidized non-
esteriﬁed fatty acids) involved in atherosclerotic plaque inﬂamma-
tion and formation of vulnerable (rupture-prone) and unstable
(symptomatic) plaques rather than stimulation of atherogenesis.4
Indeed, enhanced local expression of Lp-PLA2 in symptomatic
carotid plaques has been reported.5 In this issue, Sarlon-Bartoli went
one step further by demonstrating increased serum Lp-PLA2 in
ulcerated unstable atherosclerotic plaques and also a trend in
unstable asymptomatic carotid plaques.6 These ﬁndings have the
potential to improve cerebrovascular disease stratiﬁcation, however,
correlationwith ultrasonic orMRImarkers of plaque instability or the
presence of infarction on brain imaging was not performed.
Apart from its proposed use to reﬁne primary and secondary
risk stratiﬁcation of coronary artery disease (CAD) by lowering
LDL targets in moderate or high-risk patients,7 (pending accep-
tance by the upcoming ATP III update), increased Lp-PLA2 levels
have been suggested to appropriately classify previously mis-
classiﬁed persons who are actually at high risk of stroke and in
need of aggressive stroke intervention.8 Future studies could
investigate the role of Lp-PLA2 on embolism during carotid
stenting, or cerebrovascular risk stratiﬁcation in longitudinal
studies of patients with asymptomatic carotid stenosis. Certainly,
positive results of the STABILITY trial, which investigatesDOI of original article: 10.1016/j.ejvs.2011.10.009.
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trial in patients with carotid stenosis.
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